Next-Generation Imaging

The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.

The PSMA-targeted radiopharmaceutical 177Lu-PSMA-617 is poised to become one of the first PSMA theranostics approved by the FDA.

Tagawa draws specific attention to the targeted radioligand therapy 177Lu-PSMA-617.

The targeted radioligand therapy 177Lu-PSMA-617 also improved progression-free survival when added to best standard of care (BSC) compared with BSC alone.

At the New York GU 14th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Phillip J. Koo, MD, highlighted the potential of next-generation imaging to revolutionize the management of patients with prostate cancer.

PSA response rate was higher with the investigational radioligand therapy.

The FDA is currently reviewing the results of these trials and is scheduled to make an approval decision by May 28, 2021.

The FDA is scheduled to make a decision on a new drug application for 18F-DCFPyL on or before May 28, 2021.

The novel PSMA-targeted radiopharmaceutical for PET identified M1 disease in the majority of patients examined who otherwise had locoregional disease, according to a subanalysis of the OSPREY trial.

Twelve percent of patients with negative results on conventional imaging had lesion localization on 18F-fluciclovine PET.

Dr. Declan G. Murphy discusses results from the phase 3 proPSMA study of Ga 68 PSMA-11 in patients with high-risk prostate cancer.

The agency approved the first PSMA-targeted PET imaging drug for men with prostate cancer.

EMPIRE-1 is the first randomized trial to demonstrate an improvement in failure-free survival with treatment based on advanced molecular imaging versus conventional imaging in men with recurrent prostate cancer.

The imaging modality detected nodal metastasis with a sensitivity of 55.3% and a specificity of 84.8% in each patient.